Popular
This Week This Month
Storyboards
Sign In
to Vote &
Create Storyboards.
 

Pancreatic cancer patients with BRCA mutation may benefit from targeted drug

EurekAlert! - 14 Jun 2018 06:00
(University of Arizona Health Sciences) Rachna Shroff, M.D., led a landmark study on the use of targeted drugs called PARP inhibitors in pancreatic cancer patients with BRCA mutations.
Full Article at EurekAlert!

More Medical News
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}     {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}

    • Create Storyboard